Wantai DRD, a subsidiary of Wantai BioPharm , has made a major breakthrough in the field of biochemistry detection technology. It has successfully independently developed a biochemistry gastric four-parameter detection menu, and all four technologies have obtained national invention patent authorization. This detection series covers four indicators: Helicobacter pylori antibody, pepsinogen I, pepsinogen II, and gastrin 17, which can be simultaneously detected on a single biochemistry platform, providing an innovative solution for gastric cancer risk screening with low cost and high efficiency. The biochemistry gastric four-parameter detection is easy to operate and has a large throughput, making it suitable for large-scale population screening. The combined detection can provide objective and fair grading evaluation results for clinical practice, facilitating the early detection and precise intervention of gastric diseases.